Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sad

<< Previous

Bullboard Posts

Next >>

Comment by Rawrasauruson Aug 18, 2021 12:31am

153 Views

Post# 33721996

RE:Sad

It's because you clearly are a fud fairy. They may realize earlier than the 2 months for a full report what the issue was and wipe the three subjects from the data set entirely as an outlier leaving all remaining subjects with no known LTE. They could release a killer IND results or start disclosing their completed animal toxicology studies. You might be right. You might be wrong. Regardless, we're all just speculating with literally no basis for our claims until something is released from the company. In the meantime, you are clearly not invested in the company and appear to be short. Please leave the board.

<< Previous

Bullboard Posts

Next >>

Bombardier delivers Global 6500 aircraft to U.S. Army